Agoracom Blog Home

Posts Tagged ‘Hemp’

Namaste $N.ca $NXTTF Reaffirms Position on No US Exposure and Provides Corporate Response to Recision of Cole Memo and CSA Statement $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, January 17th, 2018

Nlogo

  • Reaffirms its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions
  • Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments

VANCOUVER, British Columbia, Jan. 17, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) would like to reaffirm its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions. Further to the Company’s Nov 28, 2017 press release, and in lieu of the recent rescission of the Cole Memorandum by US Attorney General Jeff Sessions, Namaste’s position on staying out of the US cannabis market remains firm. The Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments. Namaste is highly focused on the expansion of its Canadian operations through the launch of its online medical cannabis marketplace. Management will have no involvement in operations or investments in any illegal jurisdictions which present any risk to the Company and/or its shareholders.

On January 12, 2018, the Canadian Securities Administrators (“CSA”) issued a statement following the rescission, whereby the CSA gave notice that it would re-examine its disclosure-based policy in relation to Canadian cannabis companies with any US operations or investments. Namaste believes that the CSA’s statement is in-line with the Company’s position and short-term outlook on the cannabis market in the United States.

Namaste will continue to focus on expansion of its international operations in progressive, legal markets by leveraging its technology and existing databases of cannabis consumers in countries around the world. Namaste, through its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) is developing an online marketplace for medical cannabis that will offer patients the largest variety of product sourced from domestic and international producers. The launch of Cannmart is significant to Namaste, as the Company intends to follow the same strategy in other legal markets where it has established a strong presence.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to have divested our US assets and operations. Namaste will continue focusing its efforts on progressive, legal markets like Canada and emerging legal cannabis markets like Australia and will remain uninvolved with any US cannabis operations until there are major changes to US federal laws.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Tetra Bio-Pharma $TBP.ca Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil) $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Tuesday, January 16th, 2018

Logo tetrabiopharma rgb web

  • Received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD),
  • Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005

OTTAWA, ONTARIO–(Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

According to Health Canada data1, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1. According to an Eight Capital analysis2, the cannabis oil market is expected to reach 1.5B$ in 2024.

The launch of this trial is the first step in Tetra’s plans to commercialize natural health products with its partners. The corporation will develop cannabis-based supplements for commercialization under the Natural Health Product regulations in Canada and in other countries where regulatory authorities have a recognized pathway for approval and commercialization of such products. The trial will eventually include formulations that will be registered as drugs under Health Canada’s TPD regulatory pathway. “Tetra Bio-Pharma Inc. seeks to become an important player in the retail market post legalization and this clinical trial is part of the sales and marketing strategy required to effectively penetrate the lucrative pharmacy and health stores retail markets,” states Bernard Fortier, CEO of Tetra.

Tetra’s vision is to develop an evidence-based approach, thereby allowing pharmacists to dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are still hesitant to support the use of these products because of the lack of data supporting its medical use. Dr. Guy Chamberland, Chief Science Officer, commented: “This trial is part of Tetra’s corporate strategy to develop the science required to commercialize safe and efficacious cannabis oil products post-legalization and to create innovative oral drug formulations for the development of medicines in the management of pain, anxiety and the treatment of cancer.”

In that respect, Tetra’s scientific team is supporting the strategy by initiating a phase 1 clinical trial to characterize the safe use of these cannabis oil medicines in humans. Tetra has worked with Altasciences Clinical Research for the preparation of the Clinical Trial Application (CTA) for the conduct of a double-blind phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple daily doses of cannabis (Delta-9-tetrahydrocannabinol/Cannabidiol) oil capsules administered to healthy human volunteers. Health Canada issued a No Objection Letter for the conduct of the phase I clinical trial on January 12nd, 2018. Altasciences Clinical Research will be initiating the clinical trial activities in the coming weeks. The cannabis oil is manufactured by Tetra’s partner, Aphria Inc.

1: Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html] 2: Cannabis Sector, Eight Capital Estimates, July 2017About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com

Marijuana Company of America $MCOA Launches New CBD Product hempSMART™ Pain Cream $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:37 AM on Thursday, January 11th, 2018

15233 mcoa

  • Announced the launch of hempSMART Pain Cream
  • Each bottle of hempSMART Pain Cream is formulated with 300mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp
  • Topical wellness product is formulated to help reduce minor discomfort, support normal joint mobility, and promote muscle relaxation on areas that it is applied
  • MCOA CEO Donald Steinberg commented, “We are excited to announce the expansion of our hempSMART personal care product line to include pain management products. We will continue to expand our health and wellness lines in 2018 to include more products...”

ESCONDIDO, Calif., Jan. 11, 2018 – – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, through its wholly owned subsidiary hempSMART™, Inc., is pleased to announce the launch of hempSMART Pain Cream.

Each bottle of hempSMART Pain Cream is formulated with 300mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp. The newly developed product contains a synergistic combination of natural botanicals and full spectrum hemp extract featuring CBD, CBG and a broad range of terpenes. The Company’s proprietary blend of Ayurvedic herbs along with Menthol, Cayenne Pepper Extract, Rosemary Oil, Aloe Gel, White Willow Bark, Arnica, Wintergreen Extract and Tea Tree Oil, provides an immediate cooling and soothing sensation. This topical wellness product is formulated to help reduce minor discomfort, support normal joint mobility, and promote muscle relaxation on areas that it is applied.

MCOA CEO Donald Steinberg commented, “We are excited to announce the expansion of our hempSMART personal care product line to include pain management products. We will continue to expand our health and wellness lines in 2018 to include more products. We expect that our Pain Cream will be enthusiastically received by our affiliates and customers.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Marijuana Company of America $MCOA and Global #Hemp Group $GHG.ca Issue Final Report on New Brunswick Hemp / #CBD Project $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:38 AM on Wednesday, January 10th, 2018

15233 mcoa

  • Provides a final report on the first phase of their industrial hemp project in New Brunswick
  • In this first phase of MCOA’s and GHG’s multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season
  • Objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region

Escondido, California–(January 10, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and Global Hemp Group, Inc. (“GHG”) (CSE: GHG) (FSE: GHG) (OTC Pink: GBHPF) are pleased to provide a final report on the first phase of their industrial hemp project in New Brunswick.

On September 5, 2017, MCOA and GHG announced their joint venture to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada.

In this first phase of MCOA’s and GHG’s (the “Partners”) multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season (see Phase One Hemp Trial Results below). For this phase of the project, the Partners only grew hemp for research purposes, as this was the first time in 20 years that industrial hemp was grown in the region. The objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region.

The Partners are preparing for proposed changes to Canadian legislation expected in 2018, that will permit cannabidiol (CBD) extraction from industrial hemp. Health Canada is currently consulting industry representatives regarding regulations that will accompany the new cannabis legislation expected by July 1, 2018.

The Partners are now focusing on the next season of crops. Farmers have been recruited and a minimum of 125 acres of hemp cultivation is planned for 2018, with the goal of increasing the acreage under cultivation to 1,000 acres by year three of the project. This first commercial crop will focus on CBD extraction. The Partners are currently considering sites in northeast New Brunswick to locate their processing facilities. In addition, discussions are underway regarding the purchase of extraction equipment for cannabinoids, and straw processing equipment for building materials. The companies expect the facilities to be in place and operational for the 2018 harvest in October.

Under the joint venture MCOA will facilitate access to international markets for the project’s CBD production, product development and distribution, while GHG will provide technical and management expertise. MCOA has Right of First Refusal as the primary off-taker of the cannabinoids from all future hemp cultivation projects.

RENEWAL OF GHG’S HEMP LICENSE IN CANADA

GHG’s industrial hemp license was renewed for 2018. Under current legislation, hemp flowers and leaves grown under field conditions cannot be processed. It is expected that this will be allowed under new 2018 regulations, but will still require additional licenses: one to extract the CBD and another to sell CBD for medical or non-medical purposes. In anticipation of this change, GHG will be applying for a license under the Narcotics Control Regulations (NCR) to extract CBD, and an additional license under the Access to Cannabis for Medical Purposes (ACMPR) to sell it to wholesale and retail customers in Canada.

FINAL TRIAL RESULTS

The trial consisted of fifteen test plots with three different varieties and as many planting densities of hemp, in two different locations east and west of Bathurst.

The trials were sampled, and collected materials were measured at Collège Communautaire du Nouveau Brunswick (CCNB), Grand Falls laboratory, where standard drying and measuring procedures were applied to the hemp straw, flowers, and leaves. Straw yields averaged 1.0-2.5 T/ha, whereas the combined flowers and leaves of the plant averaged 1.25-2.10 T/ha. The Partners are confident that with an earlier planting date, adequate soil preparation, and a higher fertilizer application, yields will be improved in future seasons.

Cannabinoid analysis of the flowers and leaves was completed by RPC – Science & Engineering (RPC), an accredited laboratory located in Fredericton, NB. Contrary to expectations leaves, rather than the flowers, contained a greater concentration of CBD, largely explained by laboratory procedures. The highest concentration that was found was the CFX-1 leaf sample that resulted in 1.46% for the 30 kg/ha plant density compared to 1.17% for the flowers. Also, it should be noted that the CBD concentration in flowers is consistently higher at densities of 30 kg/ha across all varieties that were tested.

Frank Giese, an advisor to GHG, will consult on the 2018 cultivation to assist in increasing both plant yield and cannabinoid production. Through his experience, he has bridged the fundamentals of scientific research and hemp/cannabis breeding, as well as the use and development of modern cultivation and processing techniques in his breeding work. He has become proficient in breeding cannabinoid rich varieties of hemp, as well as being very experienced in auto flower breeding.

Donald Steinberg, CEO of MCOA, stated, “We are excited to complete the first phase of industrial hemp trials in Canada, and we look forward to continue expanding operations in Canada. Our joint venture with GHG allows MCOA the opportunity to expand the Company’s operations on an international level. Both Companies are excited about the endless possibilities for hemp derived CBD product this year in Canada.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.

Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and value, and establish a greater collective valuation.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office

Marijuana Company of America’s $MCOA Overview of 2017 Highlights $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:47 AM on Wednesday, January 3rd, 2018

15233 mcoa

2017 HIGHLIGHTS

  • MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017
  • In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc
  • In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick
  • In October 2017, MCOA and GHG jointly entered into a letter of intent  with Space Cowboys, Inc.

Escondido, California–(January 3, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce its 2017 year-end review to its valued shareholders and interested parties.

Donald Steinberg, CEO of MCOA, said: I am the founder of multiple startups, including Medical Marijuana Inc. (OTC: MJNA), which has a market cap of over 300 million dollars. I am aware of the challenges and opportunities these endeavors present, and the need for a strong foundation to build upon. Having experience in the structuring, development and operations of large global marketing companies in various industries, I believe Marijuana Company of America and its subsidiary hempSMART are poised to deliver significant value to our shareholders based on the foundations and accomplishments made in the past year. 

The Company has fulfilled its promise to its shareholders by becoming an audited and fully transparent reporting company with the Securities and Exchange Commission. We are participating in the cannabis space with our leasing operation in Washington. The hempSMART team has developed a line of products that can be viewed at www.hempsmart.com. We completed joint hemp trials in New Brunswick, Canada with Global Hemp Group, Inc. in 2017, and we expect to be starting commercial production in Spring 2018. There are a number of other projects we are completing due diligence on. I am thankful to the teams at MCOA and hempSMART for their accomplishments and due diligence in working through these various projects.  We will continue to build upon the diligent work of the past year as we continue to move forward and execute our business plan.”

Updates on hempSMART Products

The Company’s wholly owned subsidiary, hempSMART, Inc., distributes industrial hemp based CBD wellness products via network marketing. In September 2017, the Company completely revamped its website and network marketing platform to provide customers and affiliates with the necessary tools needed to become successful in the expanding $1.9 Trillion Wellness Industry. The Company has successfully filed a patent application with the U.S Patent and Trademark Office for full patent protection on its proprietary CBD formulation: “hempSMART™ Brain.” Also in 2017, hempSMART released two new products: “hempSMART™ Full Spectrum Drops” (Orange, Mint, Lemon, and Strawberry) and “hempSMART™ Pain Capsules.” Several more products are in development and the Company anticipates their release in Q1 2018.

Filing Form 10 with SEC and Completing Audit

MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017. A PCOAB registered audit firm (L & L CPAs PA) completed a two-year audit of the Company’s 2015 and 2016 financial statements. This is an integral step to qualifying the Company to uplist its trading tier with OTC Markets to the OTCQB. This is an important step in helping MCOA raise necessary capital to fund it projects and expand operations, as well as provide more transparent and reliable information to investors. Currently, the Company is in the process of preparing and filing an S-1 registration statement with the SEC in order to raise the necessary capital to fund its aggressive growth goals for 2018. Due to the inherent legal complexity of the cannabis industry, it took considerable effort to address SEC comments pertaining to disclosures of our business and corresponding products. We believe there is a great deal of shareholder value by the Company distinguishing itself from a majority of cannabis public companies that elect not to be fully reporting SEC filers.

Cultivation Joint Venture in Washington State

In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc. (“BV”), who plans to construct a 30,000 sq. ft. greenhouse cultivation facility in Oroville, WA. The facility will accommodate a Tier-3 production and processing I-502 tenant with years of experience in cannabis cultivation. In Q4 of 2017, MCOA completed financing of $800,000 in cash and 15 million shares of the Company’s common stock to complete the amended terms of the agreement. The delivery of the first pre-designed greenhouses, with full tracking and reporting protocols has arrived and completed construction of the six greenhouses, totaling in a one-acre footprint, is expected in Q1 2018. This joint venture project is solely for the purpose of cultivation and processing of legal marijuana within the state of Washington only and not beyond its borders. The Company will lease the turnkey property to the licensed tenant, thus acting solely as a landlord. As of December 31, 2017, the first greenhouse was purchased and in the process of being constructed.

JV with Global Hemp Group in Canada

In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick, Canada. MCOA and GHG have now completed the first phase of hemp trials, receiving research support from the Collége Communautaire du Nouveau Brunswick (CCNB). MCOA is granted a Right of First Refusal as the primary recipient of any raw materials produced from the project, which we expect will harvest its first commercial crop of 125 acres in Q4 2018.

MoneyTrac Technologies Investment

In July 2017, MCOA completed an investment of $250,000 into MoneyTrac Technology, Inc. (“MTT”), a subsidiary of Global Payout, Inc. (OTC: GOHE) in exchange for 15% equity position in the company, to help establish and market MTT as an alternative banking solution for the Cannabis industry. MTT currently has the ability to integrate and streamline electronic payment processing such as E-wallet, mobile applications, debit cards, and credit cards. Currently, MoneyTrac Technology has strategic partnerships with top cannabis services such as GreenRush, BlazeNow, High Grade Management Group, and PotSaver, which was a majority acquisition last October.

BeniHemp Investment

At the end of Q4, the Company announced an investment of $100,000 for a 25% equity stake in Convenient Hemp Mart, LLC’s “BeniHemp” branded products to target convenience stores for CBD product distribution. BeniHemp products will include topicals, tinctures, and edibles conveniently packaged in 1-day, 2-day, and 30-day supplies. The target market is convenience stores, smoke shops, gas stations and similar small retail businesses. The expectation is that there will be a full launch and website online in January 2018.

Space Cowboys, Inc.

In October 2017, MCOA and GHG (“the Companies”) jointly entered into a letter of intent (LOI) with Space Cowboys, Inc. (“Space Cowboys“). Pursuant to the terms of the LOI, the Companies intended to invest US$2.5 Million in exchange for a 25% equity interest in Space Cowboys. However, the Companies are unable to complete due diligence and will not be moving forward with this project.

Joint Venture in Adelanto, CA

In March, MCOA entered into a joint venture agreement with GateC Research Inc. (“GCR”) for the purpose of developing a turnkey cultivation facility in Adelanto, California for leasing to GCR which owns a local permit for cultivation. GCR and MCOA are in the process of identifying and securing property to facilitate the project. MCOA will invest cash and stock to complete the agreement. With the recent legalization of cannabis for recreational use on January 1, 2018 in California, MCOA expects to focus its attention on actualizing this opportunity in California. This JV project is solely for the purpose of cultivation of legal marijuana within the state of California and not beyond its borders. The Company will act solely as a landlord in this JV.

Investor Relations

Also in 2017, MCOA engaged NetworkNewsWire (“NNW”) for the Company’s corporate communication solutions. NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with MCOA, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.

About Marijuana Company of America, Inc.
MCOA
is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About MoneyTrac Technology
MoneyTrac Technology, Inc. is a pioneer in offering a full-service solution for alternative banking and electronic financial solutions and provides all aspects of financial technology including E-Wallet and mobile apps services for businesses and companies in various “high-risk” industries. MoneyTrac’s technology platform allows for its clients to access their financial information from anywhere in the world, in addition to providing tracking and compliance to help them manage and control the flow of all revenue through their business.

About Global Hemp Group Inc.
Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and establish a greater collective valuation.

About Bougainville Ventures, Inc.
Bougainville Ventures Inc. is in the business of investing in high grow companies and industries that lease land, equipment and other growing infrastructure to licensed marijuana producers and luxury crop growers. Bougainville itself is not a licensed marijuana grower or retailer but instead focuses on providing capital to companies which act as landlords and equipment leasing companies to licensed marijuana producers and luxury crop growers. The Company is in the process of being listed on the CSE in Canada.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Tetra Bio-Pharma $TBP.ca Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary $AERO $CBDS $CGRW $APH.ca $GBLX #CBD #Marijuana

Posted by AGORACOM-JC at 9:13 AM on Tuesday, January 2nd, 2018

Logo tetrabiopharma rgb web

  • Announced that it has entered into a share purchase agreement  with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation
  • Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc.

OTTAWA, ONTARIO–(Jan. 2, 2018) Tetra – Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement“) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors“).

Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc. (“PPP“), currently held by the Vendors (representing 20% of the issued and outstanding shares of PPP) for an aggregate purchase price (the “Purchase Price“) of $12,425,089 (the “Transaction“). Upon completion of the Transaction, PPP will become a wholly-owned subsidiary of Tetra.

“Upon completion, this transaction will be a significant milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO.

“The two selling shareholders – our Chairman and our Chief Scientific Officer – are both committed to the long-term success of Tetra as evidenced by their agreement to accept shares in Tetra in lieu of an all- cash transaction. As well, a percentage of those shares are going to be released once certain key milestones for the company have been reached,” he said.

“This transaction will allow Tetra to gain 100% control of Phytopain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives our company full flexibility to enter into other partnerships or agreements in the future.”

The Transaction is subject to customary closing conditions including, but not limited to, approval of the TSX Venture Exchange (“TSXV“) and any other approval that may be required by the TSXV.

The Transaction

Under the terms of the Purchase Agreement, the Purchase Price for the Transaction is comprised of the following:

  • Cash: An aggregate cash payment of $248,000 (the “Cash Payment“). Under the terms of the Purchase Agreement, the Cash Payment is payable in escrow as of the signature of the Purchase Agreement and has been paid to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV. In addition, Tetra has agreed to pay the Vendors, immediately upon signature of the Purchase Agreement, a non-refundable amount of $200,000, payable out of the funds available for the Cash Payment, to induce the Vendors to provide an exclusivity of negotiation to the Purchaser for the Transaction.
  • Promissory Notes: Promissory notes issued by Tetra to the Vendors in an aggregate principal amount of $2,236,696 (the “Notes“), which Notes are payable in accordance with a specified milestone schedule as described in the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Notes have been delivered to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV.
  • Tetra Shares: Common shares of Tetra (“Common Shares“) will be issued to the Vendors as follows:
    • Upon completion of the Transaction, an aggregate of 2,485,218 Common Shares will be issued to the Vendors.
    • Upon completion of the Transaction, 7,455,653 Common Shares will be issued to
      Computershare Trust Company of Canada, as escrow agent (the “Escrow Agent“), to be held in escrow and released by the Escrow Agent under the terms and conditions set forth in the Purchase Agreement and the terms and conditions of an escrow agreement to be executed at closing by the Vendors, the Corporation and the Escrow Agent.

The Vendors under the Purchase Agreement are entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation and are therefore considered “non-arm’s length parties” under the rules of the TSXV. Mr. Rancourt and Mr. Chamberland have properly disclosed their respective interest in the Transaction to the board of directors of the Corporation.

The Transaction constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). While MI 61-101 would generally subject the transaction to minority shareholder approval and formal valuation requirements, the Corporation will avail itself of the exemptions applicable under Section 5.5(a) of MI 61- 101.

Mr. Rancourt currently has ownership or direction and control over (i) an aggregate of 465,000 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 0.37% of the issued and outstanding Common Shares on a non- diluted basis and approximately 4.66% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Rancourt are released to Mr. Rancourt or an affiliate of Mr. Rancourt in accordance with the Purchase Agreement, Mr. Rancourt would then have ownership or direction and control over (i) 5,435,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.20% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.17% of the issued and outstanding Common Shares.

Mr. Chamberland currently has ownership or direction and control over (i) an aggregate of 1,250,000 Common Shares, (ii) 350,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 1.00% of the issued and outstanding Common Shares on a non-diluted basis and approximately 4.32% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Chamberland are released to Mr. Chamberland or an affiliate of Mr. Chamberland in accordance with the Purchase Agreement, Mr. Chamberland would then have ownership or direction and control over (i) 6,220,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.78% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.70% of the issued and outstanding Common Shares.

Each of Mr. Rancourt and Mr. Chamberland proposes to acquire the common shares for investment purposes, and has no current intention to increase his beneficial ownership of, or control or direction over, securities of Tetra. These investments will be reviewed on a continuing basis and their holdings may be increased or decreased in the future.

The Transaction is subject to customary conditions including, but not limited to, approval of the TSXV. The Transaction has been unanimously approved by Tetra’s board of directors (with André Rancourt abstaining from voting) and Tetra anticipates that the Transaction will be completed in the first quarter of 2018.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Corporation, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princepsproduct offering and inhalation device; guidance on expected sales volumes associated with the Rx Princepsproduct offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Bernard Fortier, MBA
Chief Executive Officer
(514) 360-8040 Ext. 206
bernard.fortier@tetrabiopharma.com
www.tetrabiopharma.com

Namaste $N.ca Announces Wholesale Supply LOI With Israel-Based BRLEV $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:42 AM on Wednesday, December 27th, 2017

Nlogo

  • Signed a Letter of Intent (“LOI”) with BRLEV AGRICULTURAL CROPS LTD
  • BRLEV will supply CannMart with high quality medical cannabis, to be imported by CannMart from Israel and offered in the Company’s online marketplace

VANCOUVER, British Columbia, Dec. 27, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to announce that it has signed a Letter of Intent (“LOI”) with BRLEV AGRICULTURAL CROPS LTD. (“BRLEV”), through its wholly owned subsidiary, Cannmart Inc. (“CannMart”), whereby BRLEV will supply CannMart with high quality medical cannabis, to be imported by CannMart from Israel and offered in the Company’s online marketplace. BRLEV is Israel’s largest licensed producer of medical cannabis, with over 40 years of experience in commercial agricultural production and export. BRLEV will work with Namaste to export medical cannabis to the Canadian market, which will fall under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) guidelines. The LOI and the proposed medical cannabis supply agreement (“Supply Agreement”) highlight Namaste’s intentions of becoming Canada’s leading online retailer for medical cannabis products, by focusing on importation of high quality medical cannabis from industry-leading countries like Israel. Namaste believes that the demand for imported cannabis and the opportunity it presents has been largely overlooked. This deal solidifies Namaste’s commitment in seeking the best cannabis products in global markets and offering them to Canadian cannabis users.

Terms of the LOI:

  • Namaste will submit purchase orders to BRLEV for medical cannabis.
  • Namaste will provide 50% payment against each purchase order once the goods arrive at the airport and have been tested by a third-party laboratory facility. The balance of payment will be due within 30 days from the shipment date.
  • Product cost to Namaste will be determined as 30% of Namaste’s retail price.
  • Namaste will be responsible for shipping and import costs.
  • Namaste’s product branding and naming conventions for each strain will adhere to Israeli government requirements where applicable.
  • Namaste will mark each customer package with BRLEV’s name and logo.

The LOI and proposed Supply Agreement reinforce Namaste’s effort to provide imported medical cannabis products to its patients by offering the largest variety of products from domestic and international producers. BRLEV boasts one of the largest production facilities in Israel and is a strong partner for Namaste. Namaste believes that BRLEV’s existing license and infrastructure will be suited to accommodate the Company’s expected demand for high quality Israeli grown medical cannabis. Namaste is highly focused on cannabis importation for its CannMart facility and specifically on sourcing from the Israeli market. This partnership will allow Namaste to offer greater value for its patients by allowing CannMart to provide a larger offering in comparison with domestic ACMPR licensed producers.  The Company expects to see strong demand for imported cannabis products and looks forward to a growing relationship with BRLEV and its management team.

Management Commentary
Asaf Bardichev, President and CEO of BRLEV comments: “BRLEV is very excited to announce the signing of this LOI. We see Namaste as a central and leading figure in the growing Canadian retail market and see this as a great opportunity for collaboration. We believe that the partnership with Namaste that we are beginning now can be a long and lasting one. It will be one that strengthens Namaste, BRLEV, and the Canadian medical cannabis market.”

Sean Dollinger, President and CEO of Namaste comments: “While the Canadian market continues to be a leader with regards to the production of high quality cannabis, Namaste remains of the opinion that Canadian consumers will demand other high-quality products from markets abroad. Through our partnership with BRLEV, Namaste fully intends to meet that demand. This transaction represents the first of many partnerships by which Namaste intends to create the largest and most diverse marketplace for Canadian cannabis consumers. We are very pleased to have signed this LOI and are looking forward to working with the BRLEV Group. Namaste believes this represents a strong partnership based on BRLEV’s credentials and experience in cultivation and agricultural export. The BRLEV management team has exceptional talents for cultivation and production of the highest quality medical cannabis in the Israeli market. We look forward to working with BRLEV and their team in creating the most diverse offering of medical cannabis in the Canadian online retail marketplace.”

About BRLEV
The BRLEV Group manages cannabis based medicine production from mother plants to final product. The group is fully licensed in all aspects of cannabis cultivation and processing as well as in the manufacturing of cannabis based medication in Israel. With an impressive lineup of high-end facilities and over 40 years of experience in agriculture the BRLEV group meets the highest industry standards including GMP, Global Gap and Tesco. Working closely with the leading Israeli research bodies in plant genetics, virus and pest control, cannabis processing and active substance extraction, BRLEV uses state of the art methods and knowledge in cannabis cultivation and processing. The BRLEV group has also secured a cannabis trading license which enables the group to start exporting its products overseas as soon as export regulations are in place.

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

$MCOA recently announced $5 Million fixed funding commitment, Find out more #MMJ #Hemp #Marijuana

Posted by AGORACOM-JC at 3:15 PM on Thursday, August 24th, 2017

15233_mcoa

MCOA: OTC

RECENT EVENTS

  • Announced $5 Million Fixed Funding Commitment READ MORE
  • Company Announces the Filing of Form 10 Registration Statement with SEC READ MORE
  • Launch of New Website READ MORE
  • Company Invests in Global Payout’s MoneyTrac READ MORE
  • Announced Formation of Strategic Advisory Board READ MORE
  • Finalized Joint Venture Agreement With Bougainville Ventures in Washington State READ MORE 
  • Completed PCOAB Audit READ MORE

Marijuana Company of America $MCOA.us Retained The Brand Law Firm, P.A., And, Craig A. Brand, Esq. #MMJ

Posted by AGORACOM-JC at 7:39 AM on Tuesday, August 22nd, 2017

15233 mcoa

  • Retained Craig A. Brand, Esq., The Brand Law Firm P.A. (TBLF), and his cannabis consulting team to provide specialized legal support
  • Focused on complex business, banking and investments in the cannabis and hemp industry

ESCONDIDO, CA–(Aug 22, 2017) – MARIJUANA COMPANY OF AMERICA, INC. (“MCOA” or the “Company“) (OTC: MCOA), an innovative cannabis and hemp marketing company, is pleased to announce that it has retained Craig A. Brand, Esq., The Brand Law Firm P.A. (TBLF), and his cannabis consulting team to provide specialized legal support.

The Brand Law Firm, P.A. is a specialized law firm focused on complex business, banking and investments in the cannabis and hemp industry with national and international clients spanning across all sectors of the industry. From cultivation and extraction to landlords, dispensaries, product development, taxation and banking to compliance and more, TBLF provides industry expertise and is a leading source of knowledge, skill and experience in the cannabis and hemp industries. The Brand Law Firm and its legal, affiliate and consulting teams have more than 75 years of defense and industry experience, training and knowledge.

Craig A. Brand, Esq. and TBLF will provide MCOA with legal support in the areas of general corporate compliance, cannabis and hemp related matters regarding licensing, applications import/export, state, national and international government relations, regulatory analysis and compliance, securities, taxation, product and brand development, as well as introductions to the top product and service providers in the industry.

“We are very fortunate to have an attorney like Craig Brand and his team at The Brand Law Firm advising the Company in all legal matters. Having an experienced legal team led by Craig to guide us will give our Company team confidence in knowing we will always be compliant,” said CEO Donald Steinberg.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Contact:
Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club